Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Microfluidics International Corporation Appoints Thomai Panagiotou, PhD to Chief Technology Officer

Abstract:
Microfluidics International Corporation (OTCBB: MFIC) today announced that Dr. Thomai "Mimi" Panagiotou has been promoted to the position of Chief Technology Officer. Dr. Panagiotou previously held the position of Vice President of Research and Development.

Microfluidics International Corporation Appoints Thomai Panagiotou, PhD to Chief Technology Officer

NEWTON, MA | Posted on July 23rd, 2008

In this role, Dr. Panagiotou will assume responsibility for the overall direction of the Company's technology and lead Microfluidics' research and development initiatives. Central to these activities will be the ongoing development and expansion of the Company's proprietary Microfluidics Reaction Technology (MRT) which enables the optimal and consistent production of nanomaterials at smaller sizes not achievable using conventional processing methods. Dr. Panagiotou will also be charged with identifying innovative new product and technology opportunities both internally and in collaboration with strategic university and business partners. Dr. Panagiotou will report to Michael C. Ferrara, Chief Executive Officer of Microfluidics International Corporation.

"Since Mimi joined Microfluidics five years ago, she has played a leading role in advancing the Company's technology, including establishing the Microfluidics Technology Center to broaden our application across various industries and the initial development of both MRT and our plug and play machine technology platform," said Michael C. Ferrara. "Mimi's scientific expertise, her depth of industry experience and her extensive understanding of our technology and products will be important to our growth efforts as we focus on building and leveraging a robust, dynamic product portfolio."

Dr. Panagiotou received her PhD in Mechanical Engineering from Northeastern University. She has published and presented extensively in major scientific journals and international conferences in the areas of nanoencapsulation, crystallization, drug delivery, nanomaterial processing and Process Intensification. Dr. Panagiotou joined Microfluidics in 2003 as Director of Research and Development and was promoted to Vice President of Research and Development in 2005. Prior to joining Microfluidics, Dr. Panagiotou was a Manager at Arthur D. Little and TIAX LLC, and a Principal Engineer at Physical Sciences, Inc. In her previous work experience, she has provided technical leadership across a variety of projects including a multi-million dollar pulmonary insulin delivery project, the development of drug eluting coatings for stents and self healing coatings for vascular grafts. Dr. Panagiotou is also the inventor of methods and hardware to produce polymer microspheres and coatings for stents that led to the award of two patents.

####

About Microfluidics International Corporation
Microfluidics International Corporation designs, manufactures and distributes proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics applies its more than 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics’ equipment customers.

Forward-Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to our plan to achieve, maintain and/or increase growth in revenue and/or market share, to achieve, maintain, and/or increase operating profitability, and/or to achieve, maintain, and/or increase net operating profitability. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by us to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to, the following risks and uncertainties: (i) whether the performance advantages of our Microfluidizer materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the timing of orders will significantly affect quarter to quarter revenues and resulting net income results for a particular quarter, which may cause increased volatility in our stock price, (iii) whether we will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to our ability to maintain compliance with the covenants and terms of our loan agreement with our senior lender, (iv) whether our Microfluidics Reaction Technology will be adopted by customers as a means of producing innovative materials in large quantities, (v) whether we are able to deploy prototype Microfluidics Reaction Technology systems for nanoparticle production and then manufacture and introduce commercial production Microfluidics Reaction Technology equipment, and (vi) whether we will achieve a greater proportion of our sales in the future through the sale of advanced processor production systems.

Contacts:
Microfluidics International Corporation
Brian E. LeClair
617-969-5452
or
FD Ashton Partners
Michael Cummings
617-897-1532

Copyright © Microfluidics International Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Composite Pipe Long Term Testing Facility February 10th, 2016

Scientists take nanoparticle snapshots February 10th, 2016

Chemical cages: New technique advances synthetic biology February 10th, 2016

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Microfluidics/Nanofluidics

Scientists have shown how to make a low-cost yet high precision glass nanoengraving: In a joint study, scientists have developed a mechanism of laser deposition of patterns on glass with a resolution of 1000 times lower than the width of a human hair January 21st, 2016

Nanoworld 'snow blowers' carve straight channels in semiconductor surfaces: NIST, IBM researchers report important addition to toolkit of 'self-assembly' methods eyed for making useful devices December 28th, 2015

New device uses carbon nanotubes to snag molecules: Nanotube “forest” in a microfluidic channel may help detect rare proteins and viruses December 21st, 2015

A cheap, disposable device for diagnosing disease December 2nd, 2015

Announcements

Composite Pipe Long Term Testing Facility February 10th, 2016

Scientists take nanoparticle snapshots February 10th, 2016

Chemical cages: New technique advances synthetic biology February 10th, 2016

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Patents/IP/Tech Transfer/Licensing

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Joint Efforts by Iranian, Malaysian Scientists Produce Antibacterial Coatings for Isolated Areas February 4th, 2016

Silicon-based metamaterials could bring photonic circuits February 1st, 2016

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre: FDA Cleared Immuno-Oncology Technology to Resume Clinical Development for Solid Tumor Patients January 27th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Tesla NanoCoatings Gains Talents of Joe Davis as Vice President-Sales Engineer January 27th, 2016

Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016

Beneq introduces new growth strategy and company structure - Jukka Nieminen appointed President December 15th, 2015

Kerstin Kleese van Dam Named Director of Brookhaven Lab's Computational Science Initiative September 26th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic